POU6F2, a novel fusion partner of NUP98 in acute myeloid leukaemia: A case report
Yu Jeong Choi
Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorSojin Lee
Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorYoonjung Kim
Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorCorresponding Author
Saeam Shin
Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Correspondence
Saeam Shin, Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
Email: [email protected]
Kyung-A Lee, Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211, Eonju-ro, Gangnam-gu, Seoul 06273, Korea.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Kyung-A Lee
Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Correspondence
Saeam Shin, Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
Email: [email protected]
Kyung-A Lee, Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211, Eonju-ro, Gangnam-gu, Seoul 06273, Korea.
Email: [email protected]
Search for more papers by this authorYu Jeong Choi
Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorSojin Lee
Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorYoonjung Kim
Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Search for more papers by this authorCorresponding Author
Saeam Shin
Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Correspondence
Saeam Shin, Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
Email: [email protected]
Kyung-A Lee, Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211, Eonju-ro, Gangnam-gu, Seoul 06273, Korea.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Kyung-A Lee
Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Correspondence
Saeam Shin, Department of Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
Email: [email protected]
Kyung-A Lee, Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211, Eonju-ro, Gangnam-gu, Seoul 06273, Korea.
Email: [email protected]
Search for more papers by this author
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available in the article itself.
REFERENCES
- 1Juul-Dam KL, Shukla NN, Cooper TM, Cuglievan B, Heidenreich O, Kolb EA, et al. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression. Eur J Med Genet. 2023; 66:104869.
- 2 WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Vol 11. 5th ed. WHO classification of tumours series. Lyon, France: International Agency for Research on Cancer (IARC); 2024 [cited 2024 Jun 28] Available from: https://tumourclassification.iarc.who.int/chapters/63
- 3Tian J, Zhu Y, Li J, Yang G, Weng X, Huang T, et al. The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients. Blood Cancer J. 2024; 14: 81.
- 4Michmerhuizen NL, Klco JM, Mullighan CG. Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. Blood. 2020; 136: 2275–2289.
- 5Chatel G, Desai SH, Mattheyses AL, Powers MA, Fahrenkrog B. Domain topology of nucleoporin Nup98 within the nuclear pore complex. J Struct Biol. 2012; 177: 81–89.
- 6Kasper LH, Brindle PK, Schnabel CA, Pritchard CE, Cleary ML, van Deursen JM. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol Cell Biol. 1999; 19: 764–776.
- 7Eklund E. The role of Hox proteins in leukemogenesis: insights into key regulatory events in hematopoiesis. Crit Rev Oncog. 2011; 16: 65–76.
- 8Lisboa S, Cerveira N, Bizarro S, Correia C, Vieira J, Torres L, et al. POU1F1 is a novel fusion partner of NUP98 in acute myeloid leukemia with t(3;11)(p11;p15). Mol Cancer. 2013; 12: 5.
- 9Cho HJ, Gurbuz F, Stamou M, Kotan LD, Farmer SM, Can S, et al. POU6F2 mutation in humans with pubertal failure alters GnRH transcript expression. Front Endocrinol (Lausanne). 2023; 14:1203542.
- 10Gough SM, Slape CI, Aplan PD. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood. 2011; 118: 6247–6257.
- 11Kosmider O, Moreau-Gachelin F. From mice to human: the "two-hit model" of leukemogenesis. Cell Cycle. 2006; 5: 569–570.
- 12Mohanty S. NUP98 rearrangements in AML: molecular mechanisms and clinical implications. Oncogene. 2023; 3: 147–164.
